Study of Docetaxel, Capecitabine and Oxaliplatin in Advanced Stomach Cancer

Stomach Cancer Clinical Trial

Official title:

A Phase I Study of Docetaxel, Capecitabine and Oxaliplatin (DXO) in Patients With Advanced Stomach Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00446290
• Other study ID #: AMC0609
• Status: Completed
• Phase: Phase 1
• Start date: March 2006
• Est. completion date: October 2007

Study information

• Verified date: January 2020
• Source: Asan Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Considering synergism between docetaxel (D), capecitabine (X), and oxaliplatin (O) and favourable toxicity profile of oxaliplatin over cisplatin, it is to be expected that combination of docetaxel, capecitabine, and oxaliplatin (DXO) will be more effective than other regimens and feasible in advanced gastric cancer. DXO regimen can be also easily administered on out-patient setting. However, so far, DXO combination has not been tried in advanced gastric cancer. The investigators will determine maximum tolerated dose of DXO regimen in this phase I study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 22
• Est. completion date: October 2007
• Est. primary completion date: October 2007
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Histologically confirmed unresectable or metastatic advanced gastric adenocarcinoma

• Completion of adjuvant chemotherapy 6 months before the study, or no previous chemotherapy (But, patients who received docetaxel, capecitabine, or oxaliplatin as adjuvant chemotherapy should be excluded.)

• Age 18 to 70 years old

• Eastern Cooperative Oncology Group performance status 0~2

• Adequate bone marrow function: white blood cell counts >4,000/µL, absolute neutrophil count >2,000/µL, and platelets>100,000/µL

• Adequate renal function: creatinine < 1 x upper normal limit (UNL) or creatinine clearance 60ml/min

• Adequate hepatic function: bilirubin < 1.5 x UNL, aspartate aminotransferase (AST)/alanine aminotransferase (ALT) levels < 2.5 x UNL, and alkaline phosphatase < 5 x UNL (except in case of bone metastasis without any liver disease)

• Given written informed consent prior to study-specific screening procedures, with the understanding that the patient has the right to withdraw from the study at any time, without prejudice

Exclusion Criteria:

• Contraindication to any drug contained in the chemotherapy regimen

• Other tumor type than adenocarcinoma

• Presence or history of central nervous system (CNS) metastasis

• Gastric outlet or bowel obstruction

• Evidence of serious gastrointestinal bleeding

• Peripheral neuropathy > grade 1

• History of significant neurologic or psychiatric disorders

• History of another malignancy within the last five years except cured basal cell carcinoma of skin and cured carcinoma in-situ of uterine cervix

• Pregnant or lactating women, women of childbearing potential not employing adequate contraception. Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential

• Sexually active males and females (of childbearing potential) unwilling to practice conception during the study

• Clinically significant cardiac disease (e.g. severe non-compensated hypertension, non-compensated heart failure, dilated cardiomyopathy, and coronary heart disease with ST segment depression in electrocardiogram) or myocardial infarction within the last 6 months

• Serious pulmonary conditions/illness (e.g. chronic lung disease with hypoxemia)

• Serious metabolic disease such as severe non-compensated diabetes mellitus

• Serious uncontrolled intercurrent infections, or other serious uncontrolled concomitant disease

• Positive serology for the human immunodeficiency virus (HIV)

Related Conditions & MeSH terms

• Stomach Cancer
• Stomach Neoplasms

Intervention

Drug:
• Docetaxel, Capecitabine and Oxaliplatin

Locations

Country	Name	City	State
Korea, Republic of	Asan Medical Center	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Asan Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With DLTs	Dose limiting toxicity (DLTs) was determined during the Wrst two cycles of treat- ment. The definitions of DLTs were as follows: (1) grade 4 neutropenia lasting for more than 5 days, or grade 3/4 neu- tropenia with fever; (2) grade 4 thrombocytopenia; (3) any other grade 3 non-hematological toxicity (excluding alope- cia); or (4) treatment delay of more than 2 weeks following the time of planned treatment. Maximal tolerated dose was defined as that the DLTs were observed in two or more patients from a cohort of two to six patients	2 years